{"id":1882,"date":"2015-08-23T05:18:16","date_gmt":"2015-08-23T09:18:16","guid":{"rendered":"http:\/\/allphasepharma.com\/dir\/?p=1882"},"modified":"2015-08-23T05:18:16","modified_gmt":"2015-08-23T09:18:16","slug":"clinical-biofilm-studies-an-interesting-evolving-landscape","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2015\/08\/23\/1882\/clinical-biofilm-studies-an-interesting-evolving-landscape\/","title":{"rendered":"Clinical Biofilm Studies \u2013 An Interesting Evolving Landscape"},"content":{"rendered":"

\"BIOFILM<\/a><\/p>\n

A recent article on \u201cAgents that Prevent Biofilm Formation\u201d captured my interest[1]<\/a>.\u00a0 The authors reviewed the literature and mentioned many substances which have shown in-vitro efficacy in disrupting biofilm production by the main offenders, i.e., S. aureus, S. epidermidis, P. aeruginosa and K. pneumoniae.<\/p>\n

These substances come with very diverse chemical structures, some are clearly chaotropic agents disturbing the biofilm lattice, others interfere with the bacterial process of biofilm production itself.<\/p>\n

There is no doubt that biofilm impacts on antibiotic efficacy in a major way. Biofilms are not only creating a barrier for antibiotic penetration, biofilm bacteria also have a different \u2018life style\u2019, more geared towards slow reproduction[2]<\/a>.\u00a0 On wound surfaces and any kind of \u2018hardware\u2019, these infections are notoriously hard to cure.\u00a0 Even very high local concentrations of aminoglycosides several fold above MIC90<\/sub> are unable to eradicate S. epidermidis in prosthetic joint infections (gentamicin impregnated cement) or P. aeruginosa in cystic fibrosis patients (after aerosol delivery).<\/p>\n

A look at Clinicaltrials.gov with the search term \u2018biofilm\u2019 generated a hefty list of 40 trials. \u00a0Well, this is an interesting bunch:\u00a0 dental plaque studies, topical treatments (burns) with various substances, studies in support of basic science (histology, immunology, microbiology), for diagnostics or for new materials are on this list but not even 1 (one) biofilm inhibitor is currently being tested for systemic use in systemic infections.<\/p>\n

For topical use, a study in diabetic foot ulcers is listed as enrolling, comparing an iodine gel with standard dressing. The most interesting trial was unfortunately withdrawn because of \u2018production issues\u2019[3]<\/a>.<\/p>\n

You will be glad to learn that quite a few studies are underway on how best to disrupt denture plaques.\u00a0 A long finished study on a drug-eluting ureteral stent remains without update or publication since 2013, another example of the many ‘orphan’ studies in this repository[4]<\/a>.<\/p>\n

Well, it seems it is still early days for the anti-biofilm group of agents. With so many substances identified, some companies will eventually get lucky.\u00a0 The prospect of re-purposing antibiotics, of preventing of catheter-related (CLSI) and prosthetic device-related infections should be a major incentive for industry.<\/p>\n

So far, Big Pharma is just standing on the sidelines\u00a0while small VC companies are dedicating themselves to the cause. Agile Sciences, Arietis Pharmaceuticals (clpP activators), Cellceutix (brilacidin defensin mimetic), Contrafect (CF-301), Kane BioTech, N8 Medical (ceragenins), Polymer Therapeutics, Sarepta Therapeutics (PPMO technology) and many, many others are pushing forward; there will be a lot more visibility for the concept once PoC has been established for a compound.<\/p>\n

This may well usher into a new and very exciting era of anti-infectives development.<\/p>\n

For an up-to-date list of compound classes please refer to the reference articles listed below\u00a0[1},{5]<\/a>.<\/p>\n

References:
\n<\/strong>[1]<\/a> N Rabin.\u00a0 Future Med. Chem. 2015; 7: 647
\n[2]<\/a> K. Rumbaugh (ed) Antibiofilm Agents: From Diagnosis to Treatment to Prevention.\u00a0 Springer, 2014
\n[3]<\/a> https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01646502?term=biofilm&rank=4
\n[4]<\/a> https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00250406?term=biofilm&rank=26
\n[5]<\/a> F Sun. Future Microbiol.\u00a02013; 8: 877<\/p>\n","protected":false},"excerpt":{"rendered":"

A recent article on \u201cAgents that Prevent Biofilm Formation\u201d captured my interest[1].\u00a0 The authors reviewed the literature and mentioned many substances which have shown in-vitro efficacy in disrupting biofilm production by the main offenders, i.e., S. aureus, S. epidermidis, P. aeruginosa and K. pneumoniae. These substances come with very diverse Continue reading Clinical Biofilm Studies \u2013 An Interesting Evolving Landscape<\/span>→<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":1885,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[227,18],"tags":[1282,403,1283,1281,874,1296,876,1297,1289,1286,1284,1285,891,1292,1293,1295,1287,1288,197,1300,1290,1299,301,1298,1294,1291],"class_list":["post-1882","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recent_literature","category-the_viewpoint","tag-agile-sciences","tag-antibiotic-blog","tag-arietis-pharmaceuticals","tag-biofilm","tag-brilacidin","tag-catheter-related-infections","tag-cellceutix","tag-central-line-infections","tag-ceragenins","tag-cf-301","tag-clpp-activators","tag-contrafect","tag-cystic-fibrosis","tag-dental-plaque","tag-denture-plaque","tag-k-pneumoniae","tag-kane-biotech","tag-n8-medical","tag-p-aeruginosa","tag-pji","tag-polymer-therapeutics","tag-prosthetic-joint-infections","tag-s-aureus","tag-s-epidermidis","tag-s-mutans","tag-sarepta-therapeutics"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/08\/BIOFILM-slider.jpg?fit=640%2C180&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/p4KWFr-um","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":671,"url":"https:\/\/allphasepharma.com\/dir\/2014\/08\/02\/671\/learning-from-set-backs-the-frustrating-search-for-a-staphylococcal-vaccine\/","url_meta":{"origin":1882,"position":0},"title":"Learning from Set-Backs: The Frustrating Search for a Staphylococcal Vaccine","author":"Harald","date":"August 2, 2014","format":false,"excerpt":"Several reasons have been proposed as explanations why so many\u00a0S. aureus vaccines\u00a0have failed in clinical trials.\u00a0 Clearly, the organism has a battery of virulence factors which may require a multipronged approach and\u00a0neutralizing just a single mechanism with a specific mAb may not suffice. However, passive immunization with polyclonal antibodies did\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"IgG antibody","src":"http:\/\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/08\/antibody.jpe","width":350,"height":200},"classes":[]},{"id":420,"url":"https:\/\/allphasepharma.com\/dir\/2014\/06\/26\/420\/fighting-p-aeruginosa-part-ii\/","url_meta":{"origin":1882,"position":1},"title":"Fighting P. aeruginosa (Part II)","author":"Harald","date":"June 26, 2014","format":false,"excerpt":"At a still earlier stage of development, we found\u00a0some exciting\u00a0anti-pseudomonal compounds. First, there is BAL-30072, a sulfactam-derivative.\u00a0 It has an interesting dual MoA as it works not only as a traditional B-lactam but also as an Fe-chelator blocking bacteria from accessing this essential nutrient [i].\u00a0 It has very good anti-pseudomonas\u2026","rel":"","context":"In "The News"","block_context":{"text":"The News","link":"https:\/\/allphasepharma.com\/dir\/category\/the_news\/"},"img":{"alt_text":"PipTazo","src":"http:\/\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/06\/PipTazo.jpe","width":350,"height":200},"classes":[]},{"id":378,"url":"https:\/\/allphasepharma.com\/dir\/2014\/06\/23\/378\/fighting-p-aeruginosa-part-i\/","url_meta":{"origin":1882,"position":2},"title":"Fighting P. aeruginosa (Part I)","author":"Harald","date":"June 23, 2014","format":false,"excerpt":"It has never been easy to cure Pseudomonas aeruginosa infections.\u00a0 Few antibiotics nowadays have reliable activity against this problem pathogen that seems to have more built-in resistance features than most other Gram-negatives.\u00a0 In the past, cephalosporins, aztreonam, penems, ciprofloxacin, and aminoglycosides were useful drugs with reliably cidal activity, especially when\u2026","rel":"","context":"In "The News"","block_context":{"text":"The News","link":"https:\/\/allphasepharma.com\/dir\/category\/the_news\/"},"img":{"alt_text":"PA-01 on Agar","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/06\/PA-01-on-Agar-300x274.jpg?resize=350%2C200","width":350,"height":200},"classes":[]},{"id":3100,"url":"https:\/\/allphasepharma.com\/dir\/2017\/01\/24\/3100\/kill-mocking-bug-cre-crab-variety\/","url_meta":{"origin":1882,"position":3},"title":"To Kill A Mocking Bug – of the CRKP or CRAB Variety","author":"Harald","date":"January 24, 2017","format":false,"excerpt":"Meropenem stands out as an antibiotic to be used first in ESBL and MDR infections, given its efficacy profile and safety record (see earlier blog). It also would seem to be appropriate to use relatively high doses or prolonged infusion times \u2013 or both - to improve T>MIC for the\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/01\/Mero-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/01\/Mero-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/01\/Mero-slider.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":1693,"url":"https:\/\/allphasepharma.com\/dir\/2015\/07\/10\/1693\/brilacidin-qidp-drug-at-a-critical-juncture\/","url_meta":{"origin":1882,"position":4},"title":"Brilacidin – QIDP Drug At a Critical Juncture","author":"Harald","date":"July 10, 2015","format":false,"excerpt":"At around this time (July 2015), Cellceutix is\u00a0expected to hammer out a Phase 3 program for brilacidin, its defensin-mimetic and host-defense protein (HDP) mimic structurally similar to magainin, with FDA. Brilacidin is certainly an interesting novel compound, coming from a new class, with a unique mode of action.\u00a0 It has\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"brilacidin - slider2 copy","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/07\/brilacidin-slider2-copy1.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/07\/brilacidin-slider2-copy1.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/07\/brilacidin-slider2-copy1.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":1401,"url":"https:\/\/allphasepharma.com\/dir\/2015\/04\/30\/1401\/a-renaissance-for-old-drugs-fosfomycin-and-colistin\/","url_meta":{"origin":1882,"position":5},"title":"A Renaissance for Old Drugs: Fosfomycin and Colistin","author":"Harald","date":"April 30, 2015","format":false,"excerpt":"Fosfomycin Who would have thought that a drug that has been around since 1969 [2] could become eligible for QIDP status in 2015? Well, Zavante Therapeutics recently garnered the coveted QIDP designation for fosfomycin IV. This formulation has been available in Europe for a quite some\u00a0time but not in the\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/1882","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/comments?post=1882"}],"version-history":[{"count":3,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/1882\/revisions"}],"predecessor-version":[{"id":1886,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/1882\/revisions\/1886"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media\/1885"}],"wp:attachment":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media?parent=1882"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/categories?post=1882"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/tags?post=1882"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}